Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Nov 17;14:5029–5041. doi: 10.2147/DDDT.S266470

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 Chiu et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

Treatment response three months after TACE according to mRECIST in DEB-TACE and cTACE groups. Treatment response in DEB-TACE group was significantly higher than in cTACE group in both objective response rate (ORR), complete response plus partial response, and disease control rate (DCR), ORR plus stable disease.

Notes: One patient in the DEB-TACE group and two patients in the c-TACE group did not survive for more than three months after TACE; thus, no tumor response data could be acquired.